updated form i -...
TRANSCRIPT
SUVEN LIFE SCIENCES LIMITED SY. NO. 99, 101‐109, DASAIGUDEM VILLAGE,
SURYAPET MANDAL AND DISTRICT, TELANGANA
UPDATED FORM I
Project No. 0217‐21‐01February 2017
Suven Life Sciences Ltd., Dasaigudem (V), Suryapet (M), Nalgonda (Dist.)‐ 508 213 Phone: +91 8684‐325964/965,9392483016 Fax: +91 8684‐220515 E‐mail ID: [email protected]; [email protected]
STUDIES AND DOCUMENTATION BY TEAM Labs and Consultants B‐115‐117 & 509, Annapurna Block, Aditya Enclave, Ameerpet, Hyderabad‐500 038. Phone: 040‐23748 555/23748616, Telefax: 040‐23748666
SUBMITTED TO MINISTRY OF ENVIRONMENT, FOREST AND CLIMATE CHANGE
GOVERNMENT OF INDIA INDIRA PARYAVARAN BHAWAN, JOR BAGH ROAD, NEW DELHI
Suven Life Sciences Limited
Form I Page 1
APPENDIX – I (See Paragraph – 6)
FORM I I) Basic Information S.No. Item Details 1 Name of the Project/s Suven Life Sciences Limited 2 S. No in the Schedule 5 (f) – A category – Synthetic Organic Chemicals
(Bulk Drugs and Intermediates) 3 Proposed capacity/area/length/tonnage to
be handled/command area/lease area/number of wells to be drilled
Area Existing: 70 acres Existing Capacity: 770 Kg/day Capacity after expansion: 8356 Kg/day It is proposed to manufacture 6 products at a time on campaign basis out of 82 Products Proposal: Extension of validity of TOR TOR File No. J‐11011/340/2013‐IA.II (I) dt. 01.05.2014
4 New/Expansion/Modernization Expansion 5 Existing Capacity/Area etc. Existing Capacity: 770 Kg/day
Area Existing: 70 Acres 6 Category of Project i.e 'A' or 'B' “A” 7 Does it attract the general condition? If yes,
please specify No
8 Does it attract the Specific condition? If yes, please specify.
No
9 Location Plot/Survey/Khasra No. Plot No.s: 99, 101 to 109 Village Dasaigudem Tehsil Suryapet District Suryapet State Telangana
10 Nearest railway station/airport along with distance in km.
Nalgonda Railway Station – 34 Km – SW, Shamshabad Airport – 92Km ‐ W
11 Nearest Town, City, District Headquarters along with distance in kms.
Town & District: Suryapet ‐ 2.1 KM
12 Village Panchayats, Zilla Parishad, Municipal Corporation, Local body (complete postal address with telephone nos. to be given)
Dasaigudem
13 Name of the Applicant K.V.Seshagiri Rao 14 Registered Address Suven Life Sciences Limited
Plot No.s: 99, 101 to 109, Dasaigudem Village, Suryapet Mandal and District, Telangana
15 Address for Correspondence: Name K.V.Seshagiri Rao Designation(Owner/Partner/CEO) Asst. Vice President ‐ Operations Address Suven Life Sciences Limited
Plot No.s: 99, 101 to 109, Dasaigudem Village, Suryapet Mandal and District, Telangana.
Suven Life Sciences Limited
Form I Page 2
Pin Code 508 213 E‐mail [email protected]; [email protected],
[email protected] Telephone Number +91 8684‐325964/965
Mobile: +91 9392483016 Fax No. 08455‐224228
16 Details of alternative Sites examined, if any. Location of these sites should be shown on a topo sheet.
Not Applicable, as the proposed expansion is within the existing industry.
17 Interlinked Projects Not applicable 18 Whether separate application of interlinked
project has been submitted? Not applicable
19 If yes, date of submission ‐NA‐ 20 If no, reason 21 Whether the proposal involves
approval/clearance under: if yes, details of the same and their status to be given. (a) The Forest (Conservation) Act, 1980? (b) The Wildlife (Protection) Act, 1972? (c) The C.R.Z Notification, 1991?
‐NA‐
22 Whether there is any Government Order/Policy relevant/relating to the site?
No
23 Forest land involved (hectares) No 24 Whether there is any location pending
against the project and /or land in which the project is propose to be set up? (a) Name of the Court (b) Case No (c) Orders/directions of the Court, if any and its relevance with the proposed project.
No
Suven Life Sciences Limited
Form I Page 3
(II) Activity 1. Construction, operation or decommissioning of the Project involving actions, which will cause physical changes in the locality (topography, land use, changes in water bodies, etc.) S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate quantities /rates,
wherever possible) with source of information data 1.1 Permanent or temporary change in
land use, land cover or topography including increase in intensity of land use (with respect to local land use plan)
NO The proposal is for expansion of the existing unit. No additional land. Total Land area after proposed expansion 70 Acres.
1.2 Clearance of existing land, vegetation and buildings?
NO The proposal is for expansion of existing bulk drug and intermediate manufacturing unit.
1.3 Creation of new land uses? NO Existing – industrial 1.4 Pre‐construction investigations e.g.
bore houses, soil testing? YES Soil test done
1.5 Construction works? YES Construction activity involves creation of additional utilities like Boilers, Chilling Plant etc and Zero Liquid Discharge (ZLD) system.
1.6 Demolition works? NO No structures for demolition 1.7 Temporary sites used for
construction works or housing of construction workers?
NO Construction labor from local villages shall be employed.
1.8 Above ground buildings, structures or earthworks including linear structures, cut and fill or excavations
YES Storage facilities shall be constructed. No major cut and fill or excavation is anticipated.
1.9 Underground works including mining or tunneling?
NO No underground works like mining and tunneling.
1.10 Reclamation works? NO1.11 Dredging? NO 1.12 Offshore structures? NO 1.13 Production and manufacturing
processes? YES Enclosed in Annexure – I
1.14 Facilities for storage of goods or materials?
NO Raw materials and solvents shall be stored with in factory premises. Materials in bags and drums will be stored in properly designed warehouse with adequate safe guards. Bulk quantities of raw materials will be stored in Bulk Storage tanks in the tank farms with retention dykes.
1.15 Facilities for treatment or disposal of solid waste or liquid effluents?
YES High TDS and low TDS effluents are treated with in the plant premises. Organic waste is sent to cement plants for co‐incineration. Solid waste generated from Multiple Effect evaporators sent to TSDF. Details of waste treatment facilities presented in Annexure II.
1.16 Facilities for long term housing of NO No housing proposed
Suven Life Sciences Limited
Form I Page 4
operational workers? 1.17 New road, rail or sea traffic during
construction or operation? NO
1.18 New road, rail, air waterborne or other transport infrastructure including new or altered routes and stations, ports, airports etc?
NO
1.19 Closure or diversion of existing transport routes or infrastructure leading to changes in traffic movements?
NO
1.20 New or diverted transmission lines or pipelines?
NO
1.21 Impoundment, damming, culverting, realignment or other changes to the hydrology of watercourses or aquifers?
NO
1.22 Stream crossings? NO 1.23 Abstraction or transfers of water
form ground or surface waters? YES Total water required shall increase from 212.5 KLD to
681.5 KLD out of which 456.5 KLD shall be met from ground water and the balance 225 KLD shall be recycled water.
1.24 Changes in water bodies or the land surface affecting drainage or run‐off?
NO
1.25 Transport of personnel or materials for construction, operation or decommissioning?
YES The construction material shall be drawn from local sources within 10 – 15 km. There is no transport of personnel, as the construction workers shall be drawn from local villages.
1.26 Long‐term dismantling or decommissioning or restoration works?
NO
1.27 Ongoing activity during decommissioning which could have an impact on the environment?
NO
1.28 Influx of people to an area in either temporarily or permanently?
YES The proposed project shall increase the employment potential and hence may lead to migration to surrounding villages.
1.29 Introduction of alien species? NO 1.30 Loss of native species or genetic
diversity? NO No, as the proposed expansion is within existing unit.
1.31 Any other actions? NO
Suven Life Sciences Limited
Form I Page 5
2. Use of Natural resources for construction or operation of the Project (such as land, water, materials or energy, especially any resources which are non‐renewable or in short supply): S.No. Information/checklist confirmation Yes/No Details thereof (with approximate quantities /rates,
wherever possible) with source of information data 2.1 Land especially undeveloped or
agricultural land (ha) No Existing Unit
2.2 Water (expected source & competing users) unit: KLD
YES Total water required shall increase from 212.5 KLD to 681.5 KLD out of which 456.5 KLD shall be met from ground water and the balance 225 KLD shall be recycled water. (Water Balance Enclosed in Annexure III)
2.3 Minerals (MT) NA 2.4 Construction material – stone,
aggregates, sand / soil (expected source – MT)
YES Will be sourced from the local villages.
2.5 Forests and timber (source – MT) NO 2.6 Energy including electricity and fuels
(source, competing users) Unit: fuel (MT), energy (MW)
YES Additional coal fired boilers of 2 x 10 TPH capacity are proposed in addition to existing 1 x 3 TPH and 1 x 4 TPH coal fired boiler. It is proposed to keep 1 x 10 TPH boilers as standby. It is proposed to establish Thermic Fluid heaters of 1 Lakh K. Cal capacity for proposed expansion.
Existing backup DG sets: 500 KVA and 600 KVA. Proposed backup DG sets: 1 x 1000 KVA Will be provided to cater to emergency load requirement during load shut downs period only.
S. No
Description Capacity Existing Proposed Total after
Expansion 1 Coal Fired
Boilers (TPH) 1 x 3 1 x 4
2 x 10 * 2 x 10 1 x 3 1 x 4
2 Thermic Fluid Heater (lac K.cal/hr)
‐‐‐ 1 1
3 DG Set (KVA)** 1 x 500 1 x 600
1 x 1000 1 x 1000 1 x 600 1 x 500
2.7 Any other natural resources (use appropriate standard units)
NA
Suven Life Sciences Limited
Form I Page 6
3. Use, storage, transport, handling or production of substances or materials, which could be harmful to human health or the environment or raise concerns about actual or perceived risks to human health. S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate quantities/rates,
wherever possible) with source of information data 3.1 Use of substances or materials, which
are hazardous (as per MSIHC rules) to human health or the environment (flora, fauna, and water supplies)
YES Hazardous chemicals shall be used for manufacturing of Synthetic Organic Chemicals and intermediates. MSIHC rules shall be followed during storage, transportation and handling of raw materials. Hazardous chemicals and solvent shall be stored and handled in closed systems.
3.2 Changes in occurrence of disease or affect disease vectors (e.g. insect or water borne diseases).
NO
3.3 Affect the welfare of people e.g. by changing living conditions?
YES Shall increase the employment potential for locals and affect the living conditions for betterment.
3.4 Vulnerable groups of people who could be affected by the project e.g. hospital patients, children, the elderly etc.,
NO No sensitive receptors are present in the immediate vicinity of the site. The project shall not have any significant impact on vulnerable groups of people.
3.5 Any other causes NO
4. Production of solid wastes during construction or operation or decommissioning (MT/month) S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate quantities/rates,
wherever possible) with source of information data 4.1 Spoil, overburden or mine wastes NO 4.2 Municipal waste (domestic and or
commercial wastes) NO Wastes from canteen, other commercial wastes like
paper, empty containers etc. The canteen wastes and commercial wastes shall be in the range of 15 kg/day
4.3 Hazardous wastes (as per Hazardous Waste Management Rules)
YES Hazardous waste generation during construction shall be limited to waste oils, batteries and containers of paints etc. The quantity of hazardous wastes generated during operation contain salts from evaporators, process residue, and solvent residues, ETP sludge and filtration media etc.
4.4 Other industrial process wastes YES Enclosed at Annexure IV 4.5 Surplus product NO 4.6 Sewage sludge or other sludge from
effluent treatment YES Sludge from Effluent treatment plant and evaporation
salts shall be sent to TSDF. 4.7 Construction or demolition wastes NO Construction activity involves creation of new
production blocks, additional utilities like boilers, Chilling Plant etc and ZLD system.
4.8 Redundant machinery or equipment NO 4.9 Contaminated soils or other materials NO Structures of all waste treatment facilities are made of
concrete and also above ground to eliminate the possibility of any contamination due to seepage and for ease of maintenance.
4.10 Agricultural wastes NO 4.11 Other solid wastes YES Enclosed at Annexure IV
Suven Life Sciences Limited
Form I Page 7
5. Release of pollutants or any hazardous, toxic or noxious substances to air (Kg/hr) S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate quantities/rates,
wherever possible) with source of information data 5.1 Emissions from combustion of fossil
fuels from stationary or mobile sourcesYES Coal Shall be used as fuel. Quantity of fuel and
emissions details are enclosed in Annexure V 5.2 Emissions from production processes YES Gaseous emissions from process are HCl, HBr, SO2,
O2, and CO2. HCl, HBr, SO2 are scrubbed in two stage scrubbers. Water is used as scrubbing media in primary scrubbers and caustic in secondary scrubbers. Dilute HCl, Sodium bisulphate & Sodium bisulphite solutions are sent to ETP. Others O, CO2 are let out into atmosphere while H2 let out into atmosphere through water column.
5.3 Emissions from materials handling including storage or transport
NO Material transfer takes place in closed pipeline systems using pumps with mechanical seals.
5.4 Emissions from construction activities including plant and equipment
YES Dust may rise during transport of material and construction activity. The dust emissions shall be mitigated by water spraying on the roads within the premises.
5.5 Dust or odors from handling of materials including construction materials, sewage and waste
NO Sewage will be treated in the treatment plant.
5.6 Emissions from incineration of waste NO 5.7 Emissions from burning of waste in
open air (e.g. slash materials, construction debris)
NO
5.8 Emissions from any other sources NO
Suven Life Sciences Limited
Form I Page 8
6. Generation of Noise and Vibration, and Emissions of Light and Heat: S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate quantities/rates,
wherever possible) with source of information data with source of information data
6.1 From operation of equipment e.g. engines, ventilation plant, crushers
YES Material transport and construction equipment shall be source of noise, while transfer pumps, vacuum systems, DG sets are the sources of noise during operation.
6.2 From industrial or similar processes YES DG sets controlled by providing Acoustic Enclosures. DG sets will be used in case of power failure from TSTRANSCO.
6.3 From construction or demolition YES Noise during construction shall be due to construction equipment and emergency DG sets.
6.4 From blasting or piling NO 6.5 From construction or operational
traffic NO The increased traffic shall not have any significant
impact. 6.6 From lighting or cooling systems NO6.7 From any other sources NO
7.Risks of contamination of land or water from releases of pollutants into the ground or into sewers, surface waters, groundwater, coastal waters or the sea: S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate quantities/rates,
wherever possible) with source of information data 7.1 From handling, storage, use or
spillage of hazardous materials NO All the hazardous materials will be stored in MS/HDPE
drums, in a covered shed and no contamination of soil is expected.
7.2 From discharge of sewage or other effluents to water or the land (expected mode and place of discharge)
NO All the waste from domestic operations sent to Effluent Treatment Plant. Treated effluent will be recycled to cooling towers.
7.3 By deposition of pollutants emitted to air into the land or into water
NO All the emissions from process are controlled by providing control equipment like scrubbers, Bag filters etc.
7.4 From any other sources NO 7.5 Is there a risk of long term build up
of pollutants in environment from these sources?
NO
Suven Life Sciences Limited
Form I Page 9
8.Risk of accidents during construction or operation of the Project, which could affect human health or the environment
S.No. Information/Checklist confirmation Yes/No Details thereof (with approximate quantities/rates, wherever possible) with source of information data
8.1 From explosions, spillages, fires etc from storage, handling, use or production of hazardous substances
YES All Inbuilt Safety precautions will be adopted and there will not be any damage to environment or human health
8.2 From any other causes NA 8.3 Could the project be affected by natural disasters
causing environmental damage (e.g. Floods, earthquakes, landslides, cloudburst etc)?
NO
9.Factors which should be considered (such as consequential development) which could lead to environmental effects or the potential for cumulative impacts with other existing or planned activities in the locality S. No. Information/Checklist confirmation Yes/No Details thereof (with approximate
quantities/rates, wherever possible) with source of information data
9.1 Lead to development of supporting. facilities, ancillary development or development stimulated by the project which could have impact on the environment e.g.: • Supporting infrastructure (roads, power supply, waste or waste water treatment, etc.) • housing development • extractive industries • supply industries • other
YES The project shall enhance the socio economic status of the area, improving the employment. There are no major support industries required for this plant.
9.2 Lead to after‐use of the site, which could haven impact on the environment
NO
9.3 Set a precedent for later developments NO
9.4 Have cumulative effects due to proximity to other existing or planned projects with similar effects
NO The baseline environmental status of the surrounding areas is within the prescribed limits as observed from the Secondary data.
Suven Life Sciences Limited
Form I Page 10
(III) Environmental Sensitivity S.No. Areas Name/
Identity Aerial distance (within 15 km.) Proposed project location boundary
1 Areas protected under international conventions, national or local legislation for their ecological, landscape, cultural or other related value
NA
2 Areas which are important or sensitive for ecological reasons ‐ Wetlands, watercourses or other water bodies, coastal zone, biospheres, mountains, forests
YES Dasaigudem Cheru – 0.77 Km in SW. Pullareddycheru – 2.14 Km in NW. Nallacheru – 4.15 Km in SW. Musi River – 6.8 Km in SW. Indergonda RF – 5 Km in SE.
3 Areas used by protected, important or sensitive species of flora or fauna for breeding, nesting, foraging, resting, over wintering, migration
NA
4 Inland, coastal, marine or underground waters NO 5 State, National boundaries NO 6 Routes or facilities used by the public for access to
recreation or other tourist, pilgrim areas NO
7 Defense installations NO 8 Densely populated or built‐up area YES Durajpalli is at a distance of 1 Km in
east with population of 2600
9 Areas occupied by sensitive man‐made land uses (hospitals, schools, places of worship, community facilities)
NA 1 Km from the site
10 Areas containing important, high quality or scarce resources (ground water resources, surface resources, forestry, agriculture, fisheries, tourism, minerals)
NO
11 Areas already subjected to pollution or environmental damage. (those where existing legal environmental standards are exceeded)
NO
12 Areas susceptible to natural hazard which could cause the project to present environmental problems (earthquakes, subsidence, landslides, erosion, flooding or extreme or adverse climatic conditions)
NO
(IV) Proposed Terms of Reference for EIA studies Scope of Work of EIA The standard terms of reference (page 181‐187) issued by the Ministry of Environment Forest and Climate change shall be followed for preparation of EIA report. Any additional study proposed by the SEAC shall also be completed.
Ref: Standard Terms of Reference (TOR) for EIA/EMPO report for projects/activities requiring environmental clearance under EIA notification, 2006, MoEF & CC, GOI, April 2015.
Suven Life Sciences Limited
Form I Page 11
I hereby give the undertaking that data and information given in the application and enclosures are true to the best of my knowledge and belief and I am aware that if any part of the data and information submitted is found to be false or misleading at any stage, the project will be rejected and clearance given, if any to the project will be revoked at our risk and cost.
Date: Place: Signature of the applicant
With Name and Full Address(Project Proponent/Authorized Signatory)
K.V. Seshagiri Rao
Asst. Vice President ‐ Operations Suven Life Sciences Ltd.,
Dasaigudem Village, Suryapet Mandal and District,Telangana
SUVEN LIFE SCIENCES LIMITED SY. NO. 99, 101‐109, DASAIGUDEM VILLAGE,
SURYAPET MANDAL AND DISTRICT, TELANGANA
ANNEXURES
SUBMITTED TO MINISTRY OF ENVIRONMENT, FOREST AND CLIMATE CHANGE
GOVERNMENT OF INDIA INDIRA PARYAVARAN BHAWAN, JOR BAGH ROAD, NEW DELHI
Suven Life Sciences Ltd., Form I Annexures
Page 1
Loca
tion
Map
of S
uven
Lif
e Sc
ienc
es L
td.,
Suven Life Sciences Ltd., Form I Annexures
Page 2
R
OA
D
ROAD
SOLV
ENT
STO
RA
GE
YA
RD
.EL
ECTR
ICA
L P
AN
EL R
OO
M F
OR
N
TANDA ROAD
GA
TE
PON
D
Gre
en B
elt
ROA
DROAD
31
GATE
Gre
en B
elt
NA
TIO
NA
L
HIG
H W
AY
N
O.9
V
IJA
YA
WA
DA
T
O
HY
DER
ABA
D
Compound Wall
NA
LA
NA
LA
NA
LA
CT-1
001
GA
TE
RoadROA
D
2
Gre
en B
elt
GA
TE ENT
ROAD 25
Gre
en B
elt
Gat
e
Gre
en B
elt
Gre
en B
elt
Gat
e
Gre
en B
elt
Gat
e
Roa
d
104.
0R
oad
11
Gre
en B
elt
30
Road
27
3C
3B
3D
5A20 22
23
13
17
18
26.0
12.0
25.0
16
32
05
14A
06
08
293A
19
24
GR
EEN
BEL
T
CYCL
E S
HED
17A
MM
A. T
anks
PIT
Vac
cum
Pum
p
MA
INTE
NA
NC
E EN
GG
.OFF
ICE
07
14
33
34
GA
TE
MA
IN E
NTR
AN
CE
35
QCD
ROA
D
33323130
WO
RK
ERS
QU
AR
TER
S
2928B
LOC
K -3
MC
C
PAN
EL R
OO
M
26PA
RK
ING
SH
ED
25SE
CU
RIT
Y
24TI
ME
OFF
ICE
& P
ERSO
NA
L D
EPT.
23SO
LVEN
T ST
OR
AG
E TA
NK
S
22SO
LVEN
T D
RU
MS
STO
RE
LIQ
UID
RA
W M
ATE
RIA
L TA
NK
S
20 &
21
R.M
.STO
RE
& B
ON
DED
STO
RE
19D
RY
HC
L.PL
AN
T
17A
TOIL
LETS
17C
AN
TEEN
& M
AIN
TAN
CE
DEP
T.
15W
ATE
R S
UM
P
14Q
A &
AD
MIN
ISTR
ATI
VE
OFF
ICE
13Q
.C.D
WA
SH A
REA
1211D
RY
ING
& P
AC
KIN
G
10
OFF
ICE
08A
MM
ON
IA V
APO
UR
AB
SOR
PTIO
N S
YST
EM
076U
TILI
TY B
LOC
K
5AEL
ECTR
ICA
L TR
AN
SFO
RM
ER
05G
ENER
ATO
R R
OO
M
04PR
OD
UC
TIO
N B
LOC
K -4
, 4A
, 4B
03
BLO
CK
DES
CR
IPTI
ON
NO 0201
PRO
DU
CTI
ON
B
LOC
K -1
, 1A
,1B
PRO
DU
CTI
ON
B
LOC
K -2
PRO
DU
CTI
ON
B
LOC
K -
3 A
3 B
, 3
C ,
3 D
09B
OIL
ER H
OU
SE 4
T/ 5
T
DR
YIN
G &
PA
CK
ING
AN
D
GM
P B
LOC
K
34
CY
LIN
DER
STO
RA
GE
SHED
35
DS
TA
NK
S
DIS
PEN
SAR
Y &
TIM
E O
FFIC
E
DM
WA
TER
PLA
NT
& O
FFIC
E
ENG
G.S
TOR
E
& C
ON
F.H
ALL
STO
RE
27EF
FLU
ENT
TREA
TMEN
T PL
AN
T
16D
RU
MS
STO
RA
GE
SHED
18FA
BR
ICA
TIO
N S
HED
35
21
2.4
4.5
M W
IDE
RO
AD
4.5
M W
IDE
RO
AD
SVL
Gat
eSV
L
SVL
ROAD
4.5
M W
IDE
RO
AD
4.5
M W
IDE
RO
AD
SVL
SVL
SVL
SVL
4.5
M W
IDE
R
OA
D
4.5
M W
IDE
R
OA
D
SVL
Stor
e
SVL
SVL
6.0
M W
IDE
RO
AD
6.0 m Road6.0 m Road
SVL
SVL
SVL
SVL
SVL
SVL
SVL
SVL
TAN
KS
5.0 M WIDE ROAD
15
26
Futu
re
GR
EEN
BEL
T
RO
AD
28
09
PLA
NT
LA
YO
UT
Title
:
Effe
ctiv
e D
ate
:D
WG
.No
: SU
VEN
- 01-
001
Prep
ared
by:
Che
cked
by
:A
ppro
ved
by
:
UN
IT -
1,
DA
SAIG
UD
EM V
ILLA
GE,
SUR
YA
PET(
M) ,
NA
LGO
ND
A (
D.T
), A
.P
121B
1A
104B
10A
Rev
.0
36
Plan
t Lay
out o
f Suv
en L
ife
Scie
nces
Ltd
.,
Suven Life Sciences Ltd., Form I Annexures
Page 3
ANNEXURE - I
M/s. Suven Life Sciences Ltd., obtained consent for establishment and operation for Bulk
Drugs & intermediates at Sy. No. 99, 101-109, Dasaigudem village, Suryapet mandal,
Nalgonda district, Andhra Pradesh. It is proposed to expand the manufacturing capacity
to meet the increasing market demands. The expansion entails a capital cost of Rs. 25
crores towards modernization of zero liquid discharge facility, debottlenecking by way of
incorporating the advanced technology and state of the art equipment. The proposed
expansion does not involve any additional civil construction for manufacturing blocks
except utility and pollution control related works. Manufacturing capacity is presented in
Table A-1. The proposed manufacturing capacity is presented in Table A-2.
Table A-1 Manufacturing Capacity – Permitted
S. No Name of the Product Quantity (Kg/day)
GROUP 1 — Regular Products 1 Cyano Acetic Acid (CAA) 413 2 Methyl-2-(Chloromethyl Phenyl)-3-Methoxy-2-Acrilate(MCPMA) 406
GROUP 2 — Campaign Products 3 Theobromine 121.6 4 Lamotrigine 31 5 Pamabrom 26.95
GROUP 3 — Campaign Products 6 2,4-Dichloropyrimidine 40 7 5-Cyano Pthalide 15 8 Homoveratryl amine (HVA) 60 9 D-mannose 235.4
10 Cyanoacetamide 60 11 4,6-dichloro-2-methyl pyrimidine 25 12 Malonic acid 60 13 2,5 Diamino-4,6-Dichloro Pyrimidine 8 14 2-Amino-5-Chloro Benzamide 120 15 2-n-Butyl-4-Formyl-5-Chloro Imidazole (BCFI) 78 16 Methyl Cyanoacetate (MCA) 120 17 Ethyl Cyanoacetate (ECA) 120 18 Barbituric Acid (BBA) 120 19 123-Trizole 232.4 20 Chloro ethoxy ethyl acetate (CEEA) 34.72 21 Methyl-Napthalene-1-Methyl-amine Hydro chloride (NAP) 19.11 22 4-hydroxy-5-methyl pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl
ester (PTZN) 20.5
23 Acyclovir Crude (DACR) 40 Note: Only one product from each group will be manufactured at any point of time.
Suven Life Sciences Ltd., Form I Annexures
Page 4
Table A-2 Manufacturing Capacity – After Expansion
S. No Name of the Product Quantity (Kg/day)
1 Methyl-2-(Chloromethyl Phenyl)-3-Methoxy-2-Acrilate(MCPMA) 2167.7 2 5-Cyano pthalide 336 3 4-hydroxy-5-methyl pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid
ethyl ester (PTZN) 81
4 Gabapentine 95.9 5 Divalproex Sodium 300 6 Azacytocine 112.2 7 4,6-dichloro pyrimidine (4,6- DCPY) 227.2 8 Adenine 132 9 1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperiidne-
4-carbothiomide (MPC) 787.2
10 Losartan potassium (LP) 150.3 11 Theobromine (TBN) 243.2 12 Malonic acid 324.3 13 Cyanoacetamide 379.7 14 Barbituric Acid (BBA) 500 15 Imatanib 298.9 16 5-Fluoro-4,6-Dichloro pyrimidine (5-Fluro-4,6-DCPY) 302.9 17 1,2,3-Trizole 471.6 18 Chloro Ethoxy Ethyl Acetate (CEEA) 520.8 19 Entacapone 100 20 Calcium Acetate 180 21 Carprofen 71.4 22 Tetra hydro ribo furanose 83 23 2,4-Dichloro-5-methyl pyrimidine (2,4-DCMPY) 330 24 Piperinyl alcohol 208 25 2-Chloro-4-Methyl pyrimidine (CMP) 521.7 26 Chloro ethyliodo pyrimidine 248.1 27 Cyano Acetic Acid (CAA) 1144 28 Lamotrigen 187.9 29 Methyl Cyanoaceate (MCA) 1135.6 30 Ethyl Cyanoaceate (ECA) 2600 31 Tomsulosin 30 32 Homoveratryl Amine (HVA) 166.7 33 D-Mannose 410 34 Verapamil HCl 181.8 35 Nitazozoxanide 250 36 Zolmitripton 100 37 2-methyl pyrolidine carboxilic acid 132.5 38 Hydroxy tetrahydrofuran 213.2 39 2,5-diamino 4,6-dichloro pyrimidine (DADCP) 331.6 40 1-Tert-butoxy carbonyl amino cyclobutane carboxylic acid (BCAC) 280 41 Benzhydrol Thioacetamide (BTA) 284.5
Suven Life Sciences Ltd., Form I Annexures
Page 5
42 Benzoin 355.7 43 2-n-Butyl-4-formyl-5-chloro imidazole (BCFI) 296.5 44 Fenoprofen Calcium dihydrate 109.6 45 Capacitabine 169.5 46 Chloro propyl amino pyrazole 99 47 Fluoro Phenyl Methanone 229 48 3,5-Diacetoxy acetophenone (DAAP) 520.8 49 Bromo-iodo benzene (BIB) 473.6 50 L-Xylose 274.3 51 5-Bromo-2-iodo pyrimidine 176.3 52 8-chloro theophylline 258.9 53 S- Indoline-2-carboxilic acid 210.1 54 2,4-Dichloro-5-Nitro pyrimidine (DCNPY) 115.6 55 Dimethyl thiophenol 310.5 56 2-Amino-5-Chloro Benzoic acid (ACB acid) 266.7 57 Methyl-Napthalene-1-Methyl-amine Hydro chloride (NAP) 382.4 58 3-Hydroxy- N-benzyl pyrrolidine (BHP) 200 59 Valsartan 85.7 60 Carbonyl amino cyclo butiric acid 228 61 Metane sulfonyl-L-lucyne 202.1 62 2,4-Diamino-6-hydroxy pyrimidine (DAHP) 246.5 63 5-Chlorothiophene-2-carboxylic acid (5-CTA) 396.4 64 3,5-Dibenzoyl tartaric acid (DBTA) 436 65 Pamabromo 331.9 66 2-chloro-5-iodo benzoic acid 491.7 67 Tetra hydro isoquinoline (THIQ) 153 68 2,4-Dichloropyrimidine (2,4-DCPY) 345 69 Doxofylline 364.6 70 Dimethyl dithiophosphoric 71.4 71 Aripiprazole 142.9 72 Phentramine hydrochloride 200 73 D-Penicillamine 80.2 74 dimethyl phenyl isothiocyanate 216 75 2-Chlorothioxanthene-9-one (2-CTX) 366.5 76 2,6-dichloro-4,8-dipiperdine-1-yl-pirimido5,4d)pyrimidine (DDH) 249.8 77 Homoveratryl Amine (HOVA) 428 78 Thiozole-5-carboxaldehyde 181.5 79 2,5-Dimethylamino-2-phenyl Butan-1-Ol (RC-105) 267.2 80 Amino Dimaleate (ADM) 418.3 81 2,4,5-Trichloro pyrimidine (TCPY) 198 82 4,4-Nitro phenyl-3-marpholine(NPMP) 115.6
Total (Worst Case – 6 Products) 8356
Suven Life Sciences Ltd., Form I Annexures
Page 6
List of By-Products S.No Name of Product Stage Name of By-Product Capacity
Kg/day TPM 1 Methyl-2-(Chloromethyl
Phenyl)-3-Methoxy-2-Acrilate IV Sodium sulfate 1467.9 44.0 V Sodium hydrogen sulfate 810.2 24.3 VI Potassium chloride 671.5 20.1
2 5-Cyano Phthalide IV Sodium sulfate 313.9 9.4 3 4-hydroxy-5-methyl
pyrrolo[2,1-f][1,2,4] triazine-6-carboxylic acid ethyl ester (PTZN)
I Methylamine hydrochloride 43.9 1.3
4 Gabapentine II Ammonium sulfate 228.8 6.9 5 4,6-Dichloro pyrimidine crude I Formic acid 81.0 2.4
II Phosphoric acid 301.8 9.1 6 1-{[5-methyl-3-
(trifluoromethyl)-1H-pyrazol-1-yl]acetyl} piperiidne-4-carbothiomide (MPC)
I Sodium sulfate 415.5 12.5
7 Losartan potassium III 5,5 Dimethyl hydantoin 26.5 0.8 8 Theobromine IV Sodium bromide 154.2 4.6 9 4,6-Dichloro-5-fluoro
pyrimidine crude I Formic acid 92.8 2.8 II Phosphoric acid 359.2 10.8
10 Entacapone Aluminium hydroxide 28.8 0.9 11 Carprofen I Acetic acid 30.7 0.9
III Boric acid 5.9 0.2 V Sodium acetate 25.3 0.8
12 2-Chloro-4-Methyl pyrimidine I Sodium sulfate 337.3 10.1 13 Lamotrigine II Sodium phosphate 39.6 1.2 14 Tamsulosin Hydrochloride III Potassium chloride 4.5 0.1
IV Sodium sulfate 18.5 0.6 V Potassium bromide 12.9 0.4
VII Sodium Bromide 8.2 0.2 15 Verapamil Hydrochloride
(Pure) III Sodium bromide 38.7 1.2
16 Zolmitriptan I Sodium sulfate 164.4 4.9 17 2-methyl pyrolidine carboxilic
acid I Lithium iodide 167.4 5.0
18 3-Hydroxy tetra hydrofuran II Boric acid 314.0 9.4 Sodium sulfate 761.6 22.8
19 Benzhydral Thioacetamide II Sodium bromide 79.5 2.4 20 2-Butyl-4-formyl-5-chloro
imidazole II Ammonium phosphate 236.8 7.1
21 Fenoprofen Calcium Dihydrate IV Potassium sulfate 80.3 2.4 Manganese dioxide 80.1 2.4
22 Capacitabine I Pyridine Hydrochloride 66.0 2.0 II Sodium acetate 85.2 2.6
Suven Life Sciences Ltd., Form I Annexures
Page 7
23 Chloro propyl amino pyrazole II Lithium chloride 37.4 1.1 24 5-Bromo-2-Iodo benzene I Sodium sulfate 279.6 8.4 25 2,4-Dichloro-5 nitro
pyrimidine(DCNPY) II Phosphoric acid 230.0 6.9
26 Dimethyl thiophene II Zinc chloride 306.4 9.2 27 N-Methyl napthalene
methylmamine II Monomethyl amine HCl 148.0 4.4
28 3-Hydroxy- N-benzyl pyrrolidine
II Boric acid 137.0 4.1
29 Valsartan II Triethyl amine HBr 55.1 1.7 III Triethyl amine HCl 33.8 1.0 IV Succinic acid 59.6 1.8
30 Methane Sulfonyl L-leucyne I Potassium sulfate 47.8 1.4 III Boric acid 28.0 0.8
31 2,4-Diamino-6-hydroxy pyrimidine
I Sodium nitrate 166.3 5.0
32 Pamabrom I Sodium bromide 103.4 3.1 33 2-chloro-5-iodo benzoic acid II Potassium acetate 192.0 5.8 34 Tetra Hydro Isoquinoline III Hydrobromic acid 83.2 2.5 35 2,4-Dichloropyrimidine I Phophoric acid 453.8 13.6 36 Dimethyl phenyl
isothiocyanate I Sodium sulfate 123.2 3.7
37 2-Chlorothioxanthene-9-one III Sulfuric acid 145.6 4.4 38 2,6-dichloro-4,8-dipiperdine-1-
yl-pirimido5,4d) pyrimidine (DDH)
I Spent sulfuric acid 400.0 12.0 IV Phosphoric acid 145.3 4.4
39 Thiozole 5 Carboxyaldehyde I Acetic acid 72.8 2.2 III Phosphoric acid 192.4 5.8 IV Hydrobromic acid 71.6 2.1
40 2,5-Dimethylamino-2-phenyl Butan-1-Ol (RC105)
III Methyl sodium sulfate 195.3 5.9 IV Aluminium chloride 184.6 5.5
41 2,4,5-Trichloro pyrimidine (TCPY)
II Phosphoric acid 213.7 6.41
Suven Life Sciences Ltd., Form I Annexures
Page 8
Process Description of 5-Cyano Phthalide
Chemical Reaction of 5-Cyano Phthalide
Stage I
Stage II
O O H
OH O
T e r e p h t h a l ic a c idC 8H 6 O 4
M W : 1 6 6 .1 3
O
O
O
H O
5 -c a r bo x y p h t ha l id eC 9H 6O 4
M W : 1 7 8 .1 4
(C H 2 O )nO le u m (2 0 -2 5 % S O 3
H 2 O
M . W : 3 0 . 0
P a r a f o r m a ld e h y d e
H 2 O
Suven Life Sciences Ltd., Form I Annexures
Page 9
Process Description for 5-Cyano Phthalide
Stage – I: Terephthalic Acid and paraformaldehyde reacts in presence of Oleum forms
5-Carboxy Phthalide.
Stage – II : 5-Carboxy Phthalide treated with Thionyl Chloride,Sulfamide and DMF in
presence of Toluene + Sulfolane to get 5-Cyano Phthalide. The process flow diagram is
presented in Fig A-1 and material balance is presented in Table A-3.
Rec. Sulfolane
` Loss
5-carboxypthalideThioyl chloride
SulfolaneSulfamide
Water Effluent to Treatement SystemResidue
Rec. Acetic Acid
` Loss
Acetic AcidActivated Carbon
Residue
Solvent Recovery
Stage - I.
Stage - II
5-Cyano Phthalide
Solvent Recovery
Fig A-1 Process Flow Diagram of 5-Cyano Phthalide
Suven Life Sciences Ltd., Form I Annexures
Page 10
Table A-3 Material Balance for 5-Cyano Phthalide Stage I Input Quantity
(Kg/day) Output Quantity
(Kg/day) Remarks
5-Carboxy Phthalide 418.6 5-Cyano Phthalide 351.5 To Stage-II Sulfamide 225.7 Ammonium chloride 118.3 Inorganic residue
Thionyl chloride 279.8 Sodium hydrogen sulfite
229.9 To wastewater
Sodium hydroxide 353.7 Sodium sulfate 313.9 By product Sulfolane 950 Sodium chloride 129.3 To wastewater
DM water 4500 Water formed in reaction
79.6 To wastewater
Sulfolane Recovered 904.9 Recovered & reused Sulfolane Loss 7.6 Fugitive Loss Sulfolane to
Wastewater 11.4 To wastewater
Sulfolane to Residue 26.1 Solvent in Residue 5-Carboxy Phthalide 25.1 To wastewater Sulfamide 13.5 To wastewater Hydrogen chloride 10.3 To Scrubber Sulfur Dioxide 9 To Scrubber Sodium hydroxide 0.0 To wastewater DM water 4497.5 To wastewater Total Input 6727.8 Total Output 6727.8 Stage II Input Quantity
(Kg/day) Output Quantity
(Kg/day) Remarks
5-Cyanopthalide crude
351.5 5-Cyano Phthalide 336.00 Final Product
Acetic acid 1500 Acetic acid Recovered 1411.5 Recovered & reused Activated carbon 50 Acetic acid loss 72 Fugitive Loss Acetic acid to Residue 16.5 Solvent in Residue 5-Cyanopthalide
crude 15.5 Organic Residue
Activated Carbon 50 Spent carbon Total Input 1901.5 Total Output 1901.5
Suven Life Sciences Ltd., Form I Annexures
Page 11
ANNEXURE – II: Wastewater Treatment Facilities
The effluent generated from the proposed expansion of M/s. Suven Life Sciences Ltd., is
mainly from process, washings, scrubbers, cooling towers & boiler blow downs and
domestic effluent. Effluent from process, washings and scrubbers are sent to Stripper,
Multiple Effect Evaporator followed by ATFD, Biological treatment and RO. Cooling
towers, boiler bow downs and domestic effluents shall be sent to Biological treatment
system followed by RO. The treated effluent shall be reused for cooling towers. Total
Effluent generated and mode of treatment before and after expansion is presented in
Table A-4 and quantity and quality of effluent generated from process after expansion is
presented in Table A-5.
Table A-4 Quantity of Effluent Generated
Description Quantity (KLD) Mode of Treatment Permitted After
Expansion HTDS Effluents
Process 7.5 69.6 Sent to Stripper. Stripper condensate sent to cement industries for co-processing/TSDF. Stripper bottom sent to MEE followed by AFTD, biological treatment plant and RO. RO permeate reused for cooling towers make-up. Rejects sent to MEE.
Washings 2 50 Scrubber Effluent 0.5 27 RO/DM rejects 25
Total - I 10 171.6 LTDS Effluents
Boiler Blow downs 3 8 Sent to Biological Treatment System followed by RO. RO permeate reused for cooling tower makeup. RO rejects sent to MEE. RO permeate reused for cooling towers make-up. Rejects sent to MEE.
Cooling Tower Blow downs
30
Domestic 9 30
Total - II 12 68 Grand Total (I+II) 22 239.6
Suven Life Sciences Ltd., Form I Annexures
Page 12
Table A-5 Quantity and Quality of Effluent Generated from Process S.No Name of Product Quantity (Kg/Day) Concentration
(mg/l) Water Input
TDS COD Total Effluent
TDS COD
1 Methyl-2-(Chloromethyl Phenyl)-3-Methoxy-2-Acrilate(MCPMA)
20511 1924 538 24192 79551 22256
2 5-Cyano pthalide 4500 373 53 4986 74754 10585 3 4-hydroxy-5-methyl
pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester (PTZN)
3200 0 166 3351 0 49589
4 Gabapentine 5568 291 220 7274 40042 30193 5 Divalproex Sodium 2300 220 82 2962 74207 27563 6 Azacytocine 1000 63 8 1113 56854 7186 7 4,6-dichloro pyrimidine (4,6-
DCPY) 6327 512 22 6756 75735 3289
8 Adenine 4100 210 85 4502 46568 18846 9 1-{[5-methyl-3-
(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperiidne-4-carbothiomide (MPC)
11440 855 79 12680 67438 6208
10 Losartan potassium (LP) 4350 109 50 4514 24239 11038 11 Theobromine (TBN) 3554 355 131 5151 68998 25514 12 Malonic acid 235 0 1 123 0 6974 13 Cyanoacetamide 100 13 2 385 34642 4547 14 Barbituric Acid (BBA) 1750 230 1 2318 99189 545 15 Imatanib 897 0 0 897 0 0 16 5-Fluoro-4,6-Dichloro
pyrimidine (5-Fluro-4,6-DCPY) 7445 717 68 8199 87446 8353
17 1,2,3-Trizole 0 0 0 0 0 0 18 Chloro Ethoxy Ethyl Acetate
(CEEA) 3600 326 30 4079 79876 7242
19 Entacapone 3782 56 78 3873 14360 20026 20 Calcium Acetate 2000 6 25 2076 2880 12204 21 Carprofen 3087 79 176 3339 23719 52617 22 Tetra hydro ribo furanose 1100 52 94 1235 41945 76331 23 2,4-Dichloro-5-methyl
pyrimidine (2,4-DCMPY) 1500 460 0 1960 234711 0
24 Piperinyl alcohol 1140 12 9 1161 10189 7582 25 2-Chloro-4-Methyl pyrimidine
(CMP) 6054 500 59 6962 71852 8501
26 Chloro ethyliodo pyrimidine 2534 147 275 3148 46837 87458 27 Cyano Acetic Acid (CAA) 500 0 0 500 0 991 28 Lamotrigen 2303 15 54 2489 5901 21722
Suven Life Sciences Ltd., Form I Annexures
Page 13
29 Methyl Cyanoaceate (MCA) 500 8 3 717 11688 3485 30 Ethyl Cyanoaceate (ECA) 500 14 14 940 14805 14784 31 Tomsulosin 1690 1 3 54 13656 63330 32 Homoveratryl Amine (HVA) 200 0 5 205 0 23199 33 D-Mannose 350 0 0 350 0 0 34 Verapamil HCl 2400 114 39 2629 43299 14764 35 Nitazozoxanide 0 0 0 0 0 0 36 Zolmitripton 3660 79 60 3788 20752 15744 37 2-methyl pyrolidine carboxilic
acid 3552 90 81 3699 24303 22005
38 Hydroxy tetrahydrofuran 9290 649 127 10081 64421 12550 39 2,5-diamino 4,6-dichloro
pyrimidine (DADCP) 6031 382 150 6493 58847 23150
40 1-Tert-butoxy carbonyl amino cyclobutane carboxylic acid (BCAC)
2961 193 143 3321 58028 42933
41 Benzhydrol Thioacetamide (BTA)
1223 100 10 1381 72285 7549
42 Benzoin 800 50 59 880 56811 67382 43 2-n-Butyl-4-formyl-5-chloro
imidazole (BCFI) 1630 143 15 1915 74582 7682
44 Fenoprofen Calcium dihydrate 3603 222 141 3934 56472 35861 45 Capacitabine 2700 4 88 2770 1502 31824 46 Chloro propyl amino pyrazole 4150 54 25 4276 12523 5765 47 Fluoro Phenyl Methanone 3037 241 39 3331 72272 11707 48 3,5-Diacetoxy acetophenone
(DAAP) 0 0 0 0 0 0
49 1-Bromo -2-iodo benzene (BIB) 1500 130 42 1781 73067 23574 50 L-Xylose 800 0 41 874 0 46927 51 5-Bromo-2-iodo pyrimidine 2989 211 27 3250 65060 8371 52 8-chloro theophylline 3000 208 32 3290 63131 9821 53 S- Indoline-2-carboxilic acid 2727 159 124 2990 53263 41448 54 2,4-Dichloro-5-Nitro
pyrimidine (DCNPY) 611 37 2 557 66485 4231
55 Dimethyl thiophenol 2000 144 0 2227 64801 0 56 2-Amino-5-Chloro Benzoic acid
(ACB acid) 2681 212 6 2961 71680 1870
57 Methyl-Napthalene-1-Methyl-amine Hydro chloride (NAP)
700 21 12 782 27105 14833
58 3-Hydroxy- N-benzyl pyrrolidine (BHP)
1800 119 3 2037 58420 1571
59 Valsartan 1743 98 61 1905 51298 32236 60 Carbonyl amino cyclo butiric
acid 2000 69 34 2111 32621 16144
61 Metane sulfonyl-L-lucyne 918 70 27 1028 68280 26304 62 2,4-Diamino-6-hydroxy 2000 114 9 2305 49600 4025
Suven Life Sciences Ltd., Form I Annexures
Page 14
pyrimidine (DAHP) 63 5-Chlorothiophene-2-
carboxylic acid (5-CTA) 2942 294 15 3108 94514 4891
64 3,5-Dibenzoyl tartaric acid (DBTA)
1023 0 9 1007 0 9194
65 Pamabromo 650 9 25 698 13433 35790 66 2-chloro-5-iodo benzoic acid 6500 484 92 7173 67432 12813 67 Tetra hydro isoquinoline
(THIQ) 1620 68 41 1752 39020 23342
68 2,4-Dichloropyrimidine (2,4-DCPY)
1700 144 26 1696 85184 15209
69 Doxofylline 0 0 0 0 0 0 70 Dimethyl dithiophosphoric 200 0 4 204 0 17884 71 Aripiprazole 2180 149 60 2386 62455 25122 72 Phentramine hydrochloride 0 0 0 0 0 0 73 D-Penicillamine 3809 52 179 3996 12985 44877 74 dimethyl phenyl isothiocyanate 3215 64 0 3324 19338 0 75 2-Chlorothioxanthene-9-one (2-
CTX) 4896 238 100 5227 45493 19120
76 2,6-dichloro-4,8-dipiperdine-1-yl-pirimido5,4d)pyrimidine (DDH)
3027 80 47 3185 25004 14829
77 Homoveratryl Amine (HOVA) 1082 117 24 1296 90127 18277 78 Thiozole-5-carboxaldehyde 3259 38 85 3241 11710 26235 79 2,5-Dimethylamino-2-phenyl
Butan-1-Ol (RC-105) 3790 434 151 4410 98508 34144
80 Amino Dimaleate (ADM) 1603 69 73 1861 37345 39181 81 2,4,5-Trichloro pyrimidine
(TCPY) 1090 59 1 1232 48040 860
82 4,4-Nitro phenyl-3-marpholine(NPMP)
1800 132 15 2079 63438 7213
Worst case- 6 Products on campaign basis
61513 5158 1555 69598 74109 22336
Suven Life Sciences Ltd., Form I Annexures
Page 15
ANNEXURE – III: Water Balance
Water is required for process, scrubbers, washing, cooling tower makeup, steam
generation and domestic purposes. The total water requirement shall increase from 37.5
KLD to 681.5 KLD after expansion, out of which 456.5 KLD shall be fresh water and
balance 225 KLD shall be recycled water. The required water shall be drawn from ground
water sources in addition to reuse of treated wastewater. The water balance for daily
consumption after expansion is presented in Table A-6.
Table A-6 Total Water Balance – After Expansion
Purpose INPUT (KLD) OUTPUT (KLD) Fresh Water Recycled Water Loss Effluent
Process 61.5 69.60* Washings 50 50 Scrubber 25 27 Boiler Feed 160 152 8 Cooling Tower 50 225 245 30 RO/DM Plant 25 25 Domestic 35 5 30 Gardening 50 50 Gross Total 456.51 225 452 239.6 Total 681.5 696.6
* Process effluents contain soluble raw materials, byproducts, solvents etc
Suven Life Sciences Ltd., Form I Annexures
Page 16
ANNEXURE – IV: Solid Waste
Solid wastes are generated from the process shall be sent to TSDF/ Cement Industries for
Co-incineration. Stripper distillate shall send to TSDF/ Cement Industries for Co-
incineration. Evaporation salts from MEE and ATFD and ETP Sludge shall be sent to
TSDF. The total solid waste generated and mode of disposal is presented in Table A-7.
Table A-7 Solid Waste Details – After Expansion
S.No Description Units Permitted After Expansion
Mode of Disposal
1 Ash from Boiler TPD 6.7 Sold to Brick manufactures 2 Process Organic
residue TPD 0.082 2.63 Sent to TSDF/Cement
Industries 3 Solvent Residue TPD 1.57 Sent to TSDF/Cement
Industries 4 Spent Carbon Kg/day 73 519 Sent to TSDF/Cement
Industries 5 Process Inorganic
Residue TPD 0.008 1.52 Sent to TSDF
6 Spent Solvents KLD 48.6 Recovered within the plant premises.
7 Mixed Solvents KLD 0.1 5.4 Sent to authorized recovery units/Cement plants for co-incineration
8 Evaporation Salts TPD 1.9 11.34 Sent to TSDF 9 Stripper Distillate KLD 1.23 Sent to Cement Industries
for Co-incineration. 10 Hyflow Kg/day 217 Sent to TSDF 11 ETP Sludge Kg/day 80 Sent to TSDF 12 Detoxified
containers No.s/year 10000 After detoxification sent to
Authorized agencies 13 Waste oil LPM 550 Sent to Authorized
Recyclers 14 Used batteries No.s/year 10 18 Sent to Authorized
Recyclers
Suven Life Sciences Ltd., Form I Annexures
Page 17
ANNEXURE – V: Stack Emissions Details
The sources of air pollution from the plant are from proposed 2x 10 TPH coal fired Boilers,
1 lac K.cal/hr thermic fluid heater, existing 3 & 4 TPH Coal Fired Boilers. It is proposed to
establish DG sets of capacity 1000 KVA in addition to 600 and 500 KVA existing. The
proposed air pollution control equipment for coal fired boiler is bag filters. DG sets shall
be provided with stack heights based on the CPCB formula for effective stack height. DG
sets shall be provided with stack heights based on the CPCB formula for effective stack
height. The emission rates of SPM, SO2, NOx and SPM from each stack are presented in
Table A-8.
Table A-8 Stack Emission Details
S. No
Stack Connected to
Stack Ht (m)
Dia of stack at top(m)
Temp. of exhaust
gases (0C)
Exit Velocit
y (m/sec)
Pollutant Emission Rate
(g/sec) PM SO2 NOx
Permitted 1 3 & 4TPH Coal
fired Boilers 30 0.6 160 6.05 0.6 0.12 0.2
2 1 x 600KVA DG Set**
5 0.2 165 6.8 0.06 0.18 0.26
3 1 x 500KVA DG Set*
5 0.2 165 6.8 0.04 0.12 0.22
Proposed 1 2 x 10TPH Coal
Fired Boiler* 30 1.3 180 10.2 0.63 0.72 0.44
2 1 Lac K.cal/hr Thermic Fluid heater
12 0.3 180 5 -- 0.3 0.22
3 1 x 1000KVA DG Set**
6.5 0.2 170 10 0.09 0.25 0.38
* 1 x 10 TPH Boiler shall be kept as standby ** DG sets stack heights are above the roof level.
Suven Life Sciences Ltd., Form I Annexures
Page 18
ANNEXURE – VI: Process Emissions Details
Table A-9 Quantity of Process Emission Generated and Mode of Treatment/Disposal S.No Product Name Stage Name of Gas Quantity
(Kg/day) Mode of Treatment
1
MCPMA
I Hydrogen Chloride 505.4 To Scrubber II Ammonia 211.9 To Scrubber V
Hydrogen chloride 45.2 To Scrubber Sulfur dioxide 39.6 To Scrubber
2
5 Cyano Pthalide
I
Hydrogen chloride 10.3 To Scrubber Sulfur Dioxide 9.0 To Scrubber
3
4-hydroxy-5-methyl pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl ester (PTZN)
III
Hydrogen chloride 17.4 To Scrubber Sulfur trioxide 38.2 To Scrubber
4
Gabapentine
I Ammonia 3.0 To Scrubber II
Carbondioxide 76.3 Let into atmosphere safely
Ammonia 3.8 To Scrubber 5
Adenine
II Ammonia 28.0 To Scrubber III Hydrogen Chloride 0.3 To Scrubber IV Ammonia 17.6 To Scrubber
6
MPC
II
Hydrogen 0.5 Let into atmosphere through water column
Nitrogen 6.0 Let into atmosphere safely
III Hydrogen Chloride 94.4 To Scrubber 7 Theo Bromine III Hydrogen Bromide 126.3 To Scrubber 8 Imatinib I Hydrogen Chloride 63.5 To Scrubber 9 Entacapone II Hydrogen Chloride 40.4 To Scrubber 10 Carprofen I Hydrogen Chloride 18.7 To Scrubber 11 2,4-Dichloro-5-methyl
pyrimidine I Hydrogen Chloride 148.8 To Scrubber
12 2-Chloro-4-Methyl pyrimidine
I Hydrogen Chloride 444.8 To Scrubber
13 Lamotrigine I Carbondioxide 37.4 Let into atmosphere safely
14 Ethyl cyanoacetate I Carbondioxide 4.3 Let into atmosphere safely
15
Tamsulosin Hydrochloride
I
Hydrogen 0.0 Let into atmosphere through water column
Hydrogen Chloride 0.5 To Scrubber II Hydrogen 0.0 Let into atmosphere
Suven Life Sciences Ltd., Form I Annexures
Page 19
through water column
III Carbondioxide 1.3 Let into atmosphere safely
VIII Hydrogen Chloride 0.4 To Scrubber 16 Homoveratryl Amine I Hydrogen 0.1 Let into atmosphere
through water column
17 2-methyl pyrolidine carboxilic acid
II Hydrogen Chloride 8.9 To Scrubber
18
Hydroxy tetrahydrofuran
I
Sulfur Dioxide 347.0 To Scrubber Hydrogen Chloride 4.0 To Scrubber
II Hydrogen 51.3 Let into atmosphere through water column
19
N'-(2-Amino-4,6-dichloro pyrimidine-5-yl) formamide
III
Nitrogen 63.7 Let into atmosphere safely
Hydrogen Chloride 213.5 To Scrubber Ammonia 33.2 To Scrubber
20
1-Tert-butoxy carbonyl amino cyclobutane carboxylic acid (BCAC)
I Carbondioxide 74.3 Let into atmosphere safely
III Carbondioxide 63.7 Let into atmosphere safely
21
2-Butyl-4-formyl-5-chloro imidazole
I
Carbondioxide 37.2 Let into atmosphere safely
Hydrogen Chloride 6.8 To Scrubber II Dimethylamine 71.6 To Scrubber
22
Fenoprofen
I Carbondioxide 14.2 Let into atmosphere safely
IV
Hydrogen 0.9 Let into atmosphere through water column
Oxygen 29.5 Let into atmosphere safely
23
Fluoro Phenyl Methanone
I Carbonmonoxide 17.8 Let into atmosphere safely
Carbondioxide 28.0 Let into atmosphere safely
24 1-BROMO-2-IODO BENZENE
I Nitrogen 55.1 Let into atmosphere safely
25
L-Xylose
I
Hydrogen 0.4 Let into atmosphere through water column
Nitrogen 12.0 Let into atmosphere safely
II Carbondioxide 80.4 Let into atmosphere safely
Suven Life Sciences Ltd., Form I Annexures
Page 20
26 2-Chloro-5-Bromo pyrimidine
III Hydrogen Bromide 64.4 To Scrubber
27 8-Chloro theophylline I Hydrogen Chloride 46.4 To Scrubber 28
S-indoline-2-carboxylic acid
II
Hydrogen 0.1 Let into atmosphere through water column
Nitrogen 6.3 Let into atmosphere safely
III Ammonia 0.5 To Scrubber 29 2,4-Dichloro-5 nitro
pyrimidine II Hydrogen Chloride 211.0 To Scrubber
30 Dimethyl Thiophenol II Oxygen 71.9 Let into atmosphere safely
31
2-Amino-5-Chloro Benzoic acid
II
Carbondioxide 75.1 Let into atmosphere safely
Ammonia 2.9 To Scrubber 32 Carbonyl amino cyclo
butyric acid I Carbondioxide 46.6 Let into atmosphere
safely 33 Metane sulfonyl-L-lucyne III Hydrogen 3.7 Let into atmosphere
through water column
34 5-chlorothiophene-2-carboxylic acid
I Hydrogen Chloride 376.1 To Scrubber
35 Dibenzoyl tartaric acid I Hydrogen Chloride 139.7 To Scrubber 36 Pamabrom I Carbondioxide 44.2 Let into atmosphere
safely 37
2-chloro-5-iodo benzoic acid
I Carbondioxide 91.9 Let into atmosphere safely
II Hydrogen 3.9 Let into atmosphere through water column
III
Nitrogen 50.6 Let into atmosphere safely
Hydrogen Chloride 6.7 To Scrubber 38
Tetra Hydro Isoquinoline
I
Hydrogen 0.4 Let into atmosphere through water column
Nitrogen 10.0 Let into atmosphere safely
39 2,4-Dichloropyaimidine I Hydrogen Chloride 253.5 To Scrubber 40 Doxofylline I Carbondioxide 33.2 Let into atmosphere
safely 41
Aripiprazole
II Carbondioxide 18.3 Let into atmosphere safely
III Hydrogen Chloride 2.2 To Scrubber 42 Phentramine
Hydrochloride I Hydrogen Chloride 4.7 To Scrubber
Suven Life Sciences Ltd., Form I Annexures
Page 21
43
D-Penicillamine
I
Ammonia 2.1 To Scrubber Sulfur 3.9 Let into atmosphere
safely III Ammonia 11.0 To Scrubber
44
Dimethyl Phenyl Iso thiocyanate
I Ammonia 25.0 To Scrubber II Ammonia 22.5 To Scrubber
45 2-Chlorothioxanthene-9-one
II Ammonia 26.8 To Scrubber
46
2,6-dichloro-4,8-dipiperdine-1-yl-irimido5,4d)pyrimidine (DDH)
II Hydrogen 0.3 Let into atmosphere through water column
IV Hydrogen Chloride 108.3 To Scrubber
47
Thiozole-5-carboxaldehyde
II
Ammonia 8.2 To Scrubber Sulfur dioxide 69.9 To Scrubber
III Hydrogen sulfide 133.8 To Scrubber
48
2,5-Dimethylamino-2-phenyl Butan-1-Ol (RC-105)
I Ammonia 28.8 To Scrubber III Carbondioxide 128.2 Let into atmosphere
safely
49
Amino Dimaleate (ADM)
I
Sulfur dioxide 34.1 To Scrubber Oxygen 17.0 Let into atmosphere
safely II Oxygen 6.2 Let into atmosphere
safely IV Hydrogen 0.9 Let into atmosphere
through water column
50
2,4,5-Trichloro pyrimidine (TCPY)
I Hydrogen Chloride 45.4 To Scrubber II Hydrogen Chloride 155.4 To Scrubber
SUVEN LIFE SCIENCES LIMITED SY. NO. 99, 101‐109, DASAIGUDEM VILLAGE,
SURYAPET MANDAL AND DISTRICT, TELANGANA
STUDIES AND DOCUMENTATION BY TEAM Labs and Consultants QCI: MoE&F OM, List A-1, S.No. 150. (An ISO 9001:2008, ISO 14001:2004 & OHSAS 18001:2007 Certified Organization) B-115, Annapurna Block, Aditya Enclave Ameerpet, Hyderabad-500 038. Phone: 040-23748 555/616, Telefax: 040-23748666 Email: [email protected]